Ten-Year Study Links Hydroxyurea Use to Reduced Mortality and Hospitalizations in Sickle Cell Patients

A ten-year study has identified significant clinical outcomes for patients with sickle cell anemia treated with hydroxyurea, including reduced mortality rates, fewer hospitalizations, and improved physical development. The long-term research indicates that consistent use of the medication correlates with a decrease in serious health complications and a reduced requirement for blood transfusions among those living with the condition.

The study tracked patient health data over the course of a decade to evaluate the impact of the drug on disease progression. Researchers observed that participants receiving hydroxyurea experienced fewer acute medical crises, which directly contributed to lower hospital admission rates. Furthermore, the data shows that the treatment supports better growth and development patterns in patients, while simultaneously lowering the risk of death associated with sickle cell complications. These findings provide a comprehensive look at the long-term efficacy of hydroxyurea as a standard intervention for managing the disorder.